354 related articles for article (PubMed ID: 29500617)
1. Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?
Goldsmith D; Dellanna F; Schiestl M; Krendyukov A; Combe C
Clin Drug Investig; 2018 Jun; 38(6):481-490. PubMed ID: 29500617
[TBL] [Abstract][Full Text] [Related]
2. Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.
Aapro M; Krendyukov A; Schiestl M; Gascón P
BioDrugs; 2018 Apr; 32(2):129-135. PubMed ID: 29417431
[TBL] [Abstract][Full Text] [Related]
3. State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists.
Covic A; Abraham I
Int Urol Nephrol; 2015 Sep; 47(9):1529-39. PubMed ID: 26223197
[TBL] [Abstract][Full Text] [Related]
4. Epoetin biosimilars in Europe: five years on.
Mikhail A; Farouk M
Adv Ther; 2013 Jan; 30(1):28-40. PubMed ID: 23242745
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of biosimilar epoetins in nephrology in the United States.
Fishbane S; Shah HH
Am J Kidney Dis; 2015 Apr; 65(4):537-42. PubMed ID: 25582283
[TBL] [Abstract][Full Text] [Related]
6. Biosimilar Epoetin Zeta in Oncology and Haematology: Development and Experience following 6 Years of Use.
Michallet M; Losem C
Acta Haematol; 2016; 135(1):44-52. PubMed ID: 26426164
[TBL] [Abstract][Full Text] [Related]
7. History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology.
Kalantar-Zadeh K
Am J Nephrol; 2017; 45(3):235-247. PubMed ID: 28142147
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch.
Sagi S; Anjaneya P; Kalsekar S; Kottke A; Cohen HP
Drug Saf; 2023 Dec; 46(12):1391-1404. PubMed ID: 37902937
[TBL] [Abstract][Full Text] [Related]
9. Biosimilar Erythropoiesis-Stimulating Agents in Chronic Kidney Disease.
Shah HH; Fishbane S
Adv Chronic Kidney Dis; 2019 Jul; 26(4):267-271. PubMed ID: 31477257
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars-Emerging Role in Nephrology.
Wish JB
Clin J Am Soc Nephrol; 2019 Sep; 14(9):1391-1398. PubMed ID: 30082337
[TBL] [Abstract][Full Text] [Related]
11. How much are biosimilars used in southern Italy?: a retrospective analysis of epoetin utilization in the local health unit of Messina in the years 2010-2011.
Loiacono C; Sgroi C; Coppolino S; Cannata A; Ferrara R; Arcoraci V; Cananzi P; Savica V; Schuemie M; Caputi AP; Trifirò G
BioDrugs; 2012 Apr; 26(2):113-20. PubMed ID: 22385406
[TBL] [Abstract][Full Text] [Related]
12. Biosimilar ESAs: a comparative review.
Wilson P; Wood C
J Ren Care; 2015 Mar; 41(1):53-61. PubMed ID: 25348203
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
[TBL] [Abstract][Full Text] [Related]
14. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins.
Combe C; Tredree RL; Schellekens H
Pharmacotherapy; 2005 Jul; 25(7):954-62. PubMed ID: 16006274
[TBL] [Abstract][Full Text] [Related]
15. [Biosimilars].
Krämer I
Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
[TBL] [Abstract][Full Text] [Related]
16. Biosimilar epoetin zeta: extrapolation of indications and real world utilization experience.
Dingermann T; Scotte F
Expert Opin Biol Ther; 2016 Jul; 16(7):967-74. PubMed ID: 27227424
[TBL] [Abstract][Full Text] [Related]
17. HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience.
Dellanna F; Goldsmith D; Krendyukov A; Seidl A; Höbel N; Combe C
Drug Des Devel Ther; 2018; 12():9-14. PubMed ID: 29296077
[TBL] [Abstract][Full Text] [Related]
18. Understanding the biosimilar approval and extrapolation process-A case study of an epoetin biosimilar.
Agarwal AB; McBride A
Crit Rev Oncol Hematol; 2016 Aug; 104():98-107. PubMed ID: 27317353
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars: A consideration of the regulations in the United States and European union.
Daller J
Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
[TBL] [Abstract][Full Text] [Related]
20. Pharmacovigilance and biosimilars: considerations, needs and challenges.
Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]